Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
Healthcare
$40.49 +5.07%
+$2.47 today
- Market cap
- $116.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
52W Low $7.00High $838.13
Volume 0.05M
Average 0.06M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$36.51M
FY 2025 · Annual
Net Income
-$38.97M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.09M | 4.91M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 10.09M | 4.91M | 0 |
| Gross Margin | — | — | 100.0% | 100.0% | — |
| Research & Development | 30.7M | 35.2M | 49.43M | 46.42M | 19.52M |
| Selling, General & Admin | 11.37M | 12.09M | 12.65M | 14.64M | 16.99M |
| Operating Expenses | 42.07M | 47.28M | 62.08M | 61.06M | 36.51M |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| EBITDA | (41.88M) | (45.69M) | (47.37M) | (52.68M) | (38.86M) |
| EBITDA Margin | — | — | -469.5% | -1072.8% | — |
| Operating Income | (42.07M) | (47.28M) | (51.99M) | (56.15M) | (36.51M) |
| Operating Margin | — | — | -515.3% | -1143.4% | — |
| Interest Income | 119K | 1.52M | 4.56M | 3.42M | 1.14M |
| Interest Expense | 345K | 420K | 483K | 307K | 90K |
| Other Income / Expenses | (226K) | 1.1M | 4.07M | 3.12M | (2.45M) |
| Income Before Tax | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Pre-Tax Margin | — | — | -475.0% | -1079.9% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Net Margin | — | — | -475.0% | -1079.9% | — |
| EPS (Basic) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| EPS (Diluted) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| 607.4K | 611.71K | 500.63K | 536.44K | 766.6K | |
| 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
SPRB Earnings Waterfall · TTM
NASDAQ:SPRB · Revenue to Net Income
Key Ratios
EPS$-37.60
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$37.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-37.60, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 |
How much revenue does SPRB generate?
Spruce Biosciences, Inc. (SPRB) reported $0.00 of revenue in fiscal 2025.
Is SPRB profitable?
Spruce Biosciences, Inc. (SPRB) reported -$38.97M of net income.
Continue the stock analysis
Jump to another research area for this company.